<DOC>
	<DOCNO>NCT00781846</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , recommend phase 2 dose oral ridaforolimus administer combination intravenous bevacizumab patient advance cancer .</brief_summary>
	<brief_title>Trial Deforolimus Combination With Bevacizumab Patients With Advanced Cancers ( 8669-010 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>18 year age old Advanced metastatic solid tumor malignancy ECOG performance status less equal 1 Life expectancy great 3 month At least 4 week must elapse prior investigational therapy , chemotherapy , radiotherapy , first dose deforolimus Adequate hematological , hepatic renal function Serum cholesterol less equal 350 mg/dL triglyceride less equal 400 mg/dL Signed informed consent Women childbearing potential must negative serum pregnancy test within 7 day start therapy must use approved contraceptive method time screen 30 day last dose study drug Tumor location close proximity major blood vessel History brain metastasis , spinal cord compression , carcinomatous meningitis . Primary brain tumor ( example , glioblastoma ) allow . New brain metastasis , spinal cord compression , leptomeningeal metastasis screen CT scan MRI Hemoptysis hematemesis within 28 day prior enter trial Clinical significant unexplained bleed within 28 day prior enter trial Uncontrolled hypertension Proteinuria screen Clinically significant cardiovascular disease Newly diagnose poorly control type 1 2 diabetes Active infection require prescribe intervention Other concurrent illness , Investigator 's judgement , would either compromise patient 's safety interfere evaluation safety study drug Major surgery within 28 day trial entry , incompletely heal surgical incision ; minor surgery procedure within 7 day Pregnant breastfeed Known allergy macrolide antibiotic Known hypersensitivity component bevacizumab Concurrent treatment medication strongly induce inhibit cytochrome P450 ( CYP3A ) Known history HIV seropositivity Any condition Investigator 's judgement render patient unable fully understand provide inform consent and/or comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>